These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 30949709)

  • 21. Antibacterial Activity of Lefamulin against Pathogens Most Commonly Causing Community-Acquired Bacterial Pneumonia: SENTRY Antimicrobial Surveillance Program (2015-2016).
    Paukner S; Gelone SP; Arends SJR; Flamm RK; Sader HS
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670415
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lefamulin: a promising new pleuromutilin antibiotic in the pipeline.
    Dillon C; Guarascio AJ; Covvey JR
    Expert Rev Anti Infect Ther; 2019 Jan; 17(1):5-15. PubMed ID: 30513017
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical use of lefamulin: A first-in-class semisynthetic pleuromutilin antibiotic.
    Covvey JR; Guarascio AJ
    J Intern Med; 2022 Jan; 291(1):51-63. PubMed ID: 34425035
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oral 5-Day Lefamulin for Outpatient Management of Community-Acquired Bacterial Pneumonia: Post-hoc Analysis of the Lefamulin Evaluation Against Pneumonia (LEAP) 2 Trial.
    LoVecchio F; Schranz J; Alexander E; Mariano D; Meads A; Sandrock C; Moran GJ; Giordano PA
    J Emerg Med; 2021 Jun; 60(6):781-792. PubMed ID: 33731270
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New Antibiotic for Community-Acquired Bacterial Pneumonia.
    Aschenbrenner DS
    Am J Nurs; 2019 Dec; 119(12):20-21. PubMed ID: 31764045
    [No Abstract]   [Full Text] [Related]  

  • 26. Therapeutic potential of lefamulin in the treatment of community-acquired pneumonia.
    Perry W; Golan Y
    Future Microbiol; 2019 Jul; 14():927-939. PubMed ID: 31333062
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical Pharmacokinetics and Pharmacodynamics of Lefamulin.
    McCarthy MW
    Clin Pharmacokinet; 2021 Nov; 60(11):1387-1394. PubMed ID: 34254252
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and Pharmacokinetics Following Oral or Intravenous Lefamulin in Adults With Cystic Fibrosis.
    Sawicki GS; Wicha WW; Hiley TS; Close NC; Gelone SP; Guico-Pabia CJ
    Clin Ther; 2024 Feb; 46(2):96-103. PubMed ID: 38195348
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vivo pharmacodynamics of lefamulin, the first systemic pleuromutilin for human use, in a neutropenic murine thigh infection model.
    Wicha WW; Craig WA; Andes D
    J Antimicrob Chemother; 2019 Apr; 74(Suppl 3):iii5-iii10. PubMed ID: 30949706
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tissue Distribution of [
    Wicha WW; Henson C; Webbley K; Gelone SP
    Antimicrob Agents Chemother; 2022 Aug; 66(8):e0035522. PubMed ID: 35862748
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-inflammatory activity of lefamulin versus azithromycin and dexamethasone in vivo and in vitro in a lipopolysaccharide-induced lung neutrophilia mouse model.
    Hafner M; Paukner S; Wicha WW; Hrvačić B; Cedilak M; Faraho I; Gelone SP
    PLoS One; 2021; 16(9):e0237659. PubMed ID: 34587166
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lefamulin (Xenleta) for the Treatment of Community-Acquired Bacterial Pneumonia.
    Felix TM; Karpa K
    Am Fam Physician; 2020 Sep; 102(6):373-374. PubMed ID: 32931220
    [No Abstract]   [Full Text] [Related]  

  • 33. Development, validation, and application of an LC-MS/MS method for the quantification of the novel antibiotic drug lefamulin (Xenleta®) and its main metabolite 2R-hydroxy lefamulin in human plasma.
    Strickmann DB; Faber J; Klaassen T
    J Pharm Biomed Anal; 2021 Oct; 205():114293. PubMed ID: 34464869
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of Community-Acquired Pneumonia: A Focus on Lefamulin.
    Eraikhuemen N; Julien D; Kelly A; Lindsay T; Lazaridis D
    Infect Dis Ther; 2021 Mar; 10(1):149-163. PubMed ID: 33528794
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics and safety of lefamulin after single intravenous dose administration in subjects with impaired-hepatic function.
    Wicha WW; Marbury TC; Dowell JA; Crandon JL; Leister C; Ermer J; Gelone SP
    Pharmacotherapy; 2021 May; 41(5):457-462. PubMed ID: 33811377
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Integrative model-based comparison of target site-specific antimicrobial effects: A case study with ceftaroline and lefamulin.
    van Os W; Pham AD; Eberl S; Minichmayr IK; van Hasselt JGC; Zeitlinger M
    Int J Antimicrob Agents; 2024 May; 63(5):107148. PubMed ID: 38508535
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lefamulin for Treating Community-acquired Bacterial Pneumonia in Adult Patients Aged <65 Years.
    Tang HJ; Lai CC
    Clin Infect Dis; 2020 Sep; 71(6):1582. PubMed ID: 31822903
    [No Abstract]   [Full Text] [Related]  

  • 38. Lefamulin (Xenleta) for community-acquired bacterial pneumonia.
    Med Lett Drugs Ther; 2019 Sep; 61(1581):145-148. PubMed ID: 31599865
    [No Abstract]   [Full Text] [Related]  

  • 39.
    Jacobsson S; Paukner S; Golparian D; Jensen JS; Unemo M
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28893785
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lefamulin: a New Hope in the Field of Community-Acquired Bacterial Pneumonia.
    Adhikary S; Duggal MK; Nagendran S; Chintamaneni M; Tuli HS; Kaur G
    Curr Pharmacol Rep; 2022; 8(6):418-426. PubMed ID: 35811574
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.